Prevagen is not FDA approved. It is sold as a dietary supplement, a category of products that the FDA does not approve before they reach consumers. In fact, the FDA sent the manufacturer a warning letter in 2012 stating that Prevagen was an unapproved new drug and did not qualify as a dietary supplement. Despite this, the product remains widely available in pharmacies and grocery stores across the United States.
Why Prevagen Isn’t FDA Approved
The distinction between a dietary supplement and an FDA-approved drug is significant. Drugs must be proven safe and effective for their intended use before they can be sold. Supplements face no such requirement. Under the Dietary Supplement Health and Education Act (DSHEA), the FDA has no authority to approve dietary supplements before they hit the market, and it does not test them before they are sold to consumers. The manufacturer is responsible for ensuring its own products aren’t adulterated or mislabeled, but no independent verification is required upfront.
This means Prevagen went to market without ever demonstrating to the FDA that it works. The company did not have to submit clinical trial data proving the supplement improves memory or provides any cognitive benefit before selling it. The FDA can only step in after the fact if it identifies safety problems or misleading claims.
The FDA’s 2012 Warning Letter
The FDA did step in. In 2012, the agency sent Prevagen’s manufacturer, Quincy Bioscience, a warning letter citing two problems. First, the company had failed to report adverse events and product complaints associated with Prevagen. Second, and more notable, the FDA stated that Prevagen met the definition of an unapproved new drug rather than a dietary supplement. When a product is marketed with explicit or implied claims about treating, preventing, or curing a disease, it legally crosses the line from supplement to drug and becomes subject to drug regulations. Prevagen’s memory-loss claims put it squarely in that territory.
The FTC Lawsuit Over False Claims
The regulatory scrutiny didn’t stop with the FDA. The Federal Trade Commission and the New York State Attorney General jointly charged Quincy Bioscience with making false and unsubstantiated claims that Prevagen improves memory, provides cognitive benefits, and is “clinically shown” to work. That lawsuit stretched over seven years, including a jury trial. In December 2024, the FTC announced it had won, and a court ordered Quincy Bioscience to stop making the deceptive claims challenged in the lawsuit.
The core issue was that Prevagen’s advertising leaned heavily on scientific-sounding language without the science to back it up. The company promoted the product as clinically proven, but the evidence behind that claim was thin.
What the Science Actually Shows
Prevagen’s active ingredient is apoaequorin, a protein originally found in jellyfish. The company’s main piece of clinical evidence is a single study, sometimes called the Madison Memory Study, which enrolled 218 adults aged 40 to 91 who reported memory concerns. Participants took either apoaequorin or a placebo for 90 days and were assessed using computerized cognitive tests.
A 2022 analysis published in PubMed reviewed the available clinical evidence and found that this one study had significant limitations. The authors concluded that the clinical data supporting Prevagen’s efficacy was too limited to justify the product’s marketing claims. The “#1 pharmacist recommended” label the product carries likely reflects pharmacists’ familiarity with the brand through heavy advertising, not a professional endorsement of its effectiveness.
There’s also a more fundamental problem with how Prevagen is supposed to work. Apoaequorin is a protein, and like most proteins you swallow, it gets broken down in the stomach and intestines into individual amino acids or short chains of amino acids. There is little evidence that apoaequorin survives digestion intact, and even less evidence that it can cross the blood-brain barrier to reach the brain cells where it would theoretically need to act. In other words, the ingredient may never reach the part of the body where it claims to have an effect.
How Prevagen Stays on Shelves
If the FDA flagged Prevagen, the FTC sued over its claims, and the science is questionable, you might wonder how it’s still for sale. The answer lies in how supplements are regulated in the U.S. The system is fundamentally different from drug regulation. The FDA does not have pre-market authority over supplements. It can issue warning letters, and it can take enforcement action after a product is already being sold, but it cannot pull a supplement from shelves the way it might block an unapproved drug. The burden falls on the FDA to prove a product is unsafe or illegally marketed, rather than on the company to prove the product works.
Quincy Bioscience has been required to stop making specific deceptive claims following the FTC ruling. But the product itself, as a supplement containing apoaequorin, can continue to be sold as long as it doesn’t violate labeling and marketing rules going forward. The company can still sell Prevagen. It just can’t say what it used to say about what it does.
What This Means if You’re Considering Prevagen
Prevagen costs roughly $40 to $60 for a month’s supply depending on the formulation. For that price, you’re getting a protein that likely breaks down in your digestive system before it could reach your brain. The only clinical trial supporting it had significant methodological limitations, and a federal court found the company’s marketing claims to be deceptive.
The product is not dangerous for most people. Because apoaequorin appears to break down during digestion like any other dietary protein, it’s unlikely to cause harm. But “unlikely to cause harm” and “proven to help” are very different standards. If you’re experiencing memory concerns, the lack of FDA approval here isn’t a technicality. It reflects the absence of the rigorous testing that would tell you whether this supplement does anything at all.